TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
+47.93%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$1.08B
AUM Growth
+$1.08B
(+53%)
Cap. Flow
+$243M
Cap. Flow
% of AUM
22.47%
Top 10 Holdings %
Top 10 Hldgs %
41.77%
Holding
136
New
30
Increased
24
Reduced
21
Closed
13
Top Buys
Top Sells
| 1 |
EQRX
EQRx, Inc. Common Stock
EQRX
|
$22.4M |
| 2 |
THRD
Third Harmonic Bio
THRD
|
$11.5M |
| 3 |
NovoCure
NVCR
|
$7.95M |
| 4 |
Intellia Therapeutics
NTLA
|
$6.02M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
$5.99M |
Sector Composition
| 1 | Healthcare | 95.77% |
| 2 | Financials | 3.5% |
| 3 | Real Estate | 0.65% |
| 4 | Technology | 0.08% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Nuvation Bio
NUVB
$1.02B
| $5.29M | 0.49% | +3,500,000 | New | +$5.29M |
|
52
Dianthus Therapeutics
DNTH
$759M
| $5.24M | 0.48% | 504,242 -87,394 | -15% | -$909K |
|
53
Bio-Rad Laboratories Class A
BIO
$8.06B
| $5.17M | 0.48% | 16,000 -8,000 | -33% | -$2.58M |
|
54
Insmed
INSM
$28.8B
| $5.15M | 0.48% | 166,203 | – | – |
|
55
Black Diamond Therapeutics
BDTX
$157M
| $5.07M | 0.47% | 1,803,200 +1,403,200 | +351% | +$3.94M |
|
56
Aurinia Pharmaceuticals
AUPH
$1.58B
| $4.94M | 0.46% | 550,000 -200,000 | -27% | -$1.8M |
|
57
Ventyx Biosciences
VTYX
$171M
| $4.94M | 0.46% | +2,000,000 | New | +$4.94M |
|
58
Veritex Holdings
VBTX
$1.88B
| $4.89M | 0.45% | 210,000 | – | – |
|
|
59
BioCryst Pharmaceuticals
BCRX
$1.74B
| $4.79M | 0.44% | 800,000 -1,000,000 | -56% | -$5.99M |
|
|
RAIN
60
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $4.62M | 0.43% | 3,850,513 +110,172 | +3% | +$132K |
|
|
BPMC
61
DELISTED
Blueprint Medicines
BPMC
| $4.61M | 0.43% | +50,000 | New | +$4.61M |
|
62
US Bancorp
USB
$76B
| $4.33M | 0.4% | 100,000 | – | – |
|
63
Dynavax Technologies
DVAX
$1.19B
| $4.19M | 0.39% | 300,000 | – | – |
|
64
Bolt Biotherapeutics
BOLT
$9.85M
| $4.09M | 0.38% | 3,652,244 +95,204 | +3% | +$107K |
|
65
uniQure
QURE
$896M
| $4.06M | 0.38% | 600,000 -335,800 | -36% | -$2.27M |
|
66
Design Therapeutics
DSGN
$315M
| $3.92M | 0.36% | 1,480,675 +130,675 | +10% | +$346K |
|
|
CRGX
67
DELISTED
CARGO Therapeutics
CRGX
| $3.72M | 0.34% | +160,544 | New | +$3.72M |
|
|
SWTX
68
DELISTED
SpringWorks Therapeutics
SWTX
| $3.65M | 0.34% | +100,000 | New | +$3.65M |
|
69
Nkarta
NKTX
$151M
| $3.63M | 0.34% | 550,000 -553,638 | -50% | -$3.65M |
|
70
Bank of Hawaii
BOH
$2.71B
| $3.62M | 0.33% | 50,000 +20,000 | +67% | +$1.45M |
|
71
Acadia Pharmaceuticals
ACAD
$4.38B
| $3.58M | 0.33% | 114,400 +14,400 | +14% | +$451K |
|
72
Century Therapeutics
IPSC
$42.5M
| $3.54M | 0.33% | +1,066,440 | New | +$3.54M |
|
|
ADAP
73
Adaptimmune Therapeutics
ADAP
$15.6M
| $3.48M | 0.32% | 4,387,238 -779,716 | -15% | -$618K |
|
74
Quince Therapeutics
QNCX
$85.9M
| $3.38M | 0.31% | 3,220,000 -278,868 | -8% | -$293K |
|
75
Arvinas
ARVN
$568M
| $3.29M | 0.3% | 80,000 | – | – |
|